Tag archive of everolimus

Afinitor for prostate cancer

Afinitor s is currently in clinical trials for prostate cancer and only preliminary information is available.  For example, it is in the phase II study: Everolimus as First-Line Therapy in Treating Patients With Prostate Cancer,  NCT00976755. Several studies have been performed and published.  A phase II study (Templeton et al., 2011) investigating the activity of everolimus 10mg/daily as first-line treatment found that in 37 enrolled patients,

Read more
Everolimus for Hodgkin’s – pro
cosmos

Everolimus is an oral antineoplastic agent that targets the raptor mammalian target of rapamycin (mTORC1). The phosphatidylinositol 3-kinase/mTOR signal transduction pathway has been demonstrated to be activated in Hodgkin lymphoma (HL) and there was speculation that everolimus might be effective for this disease. Johnston et al studied everolimus in 19 patient. Patients had received a median of six prior therapies (range, 3-14) and 84% had undergone

Read more

Fatal error: Call to undefined function fw_blog_pagination() in /home/content/43/9379243/html/wp-content/themes/wisdom/tag.php on line 44